Anti-Integrin aVb6 (ITGAV & ITGB6) (STX-100) is a humanized monoclonal antibody directed against the alpha v beta 6 (αvβ6) integrin. It has a potential to be used in research on Idiopathic Pulmonary Fibrosis (IPF). MW : 144.88 kD.

Anti-Integrin b1 / ITGB1 / CD29 is a humanized monoclonal antibody directed against the human integrin receptor beta-1 subunit (CD29), with potential antineoplastic activity. MW: 145.5 kD.

Anti-Integrin b1 / ITGB1 / CD29 is a humanized monoclonal antibody directed against the human integrin receptor beta-1 subunit (CD29), with potential antineoplastic activity. MW: 145.5 kD.

Anti-Integrin b1 / ITGB1 / CD29 is a humanized monoclonal antibody directed against the human integrin receptor beta-1 subunit (CD29), with potential antineoplastic activity. MW: 145.5 kD.

Anti-KAAG1 (ADCT-901-MMAE) is an ADC composed of a humanized monoclonal antibody (3A4) targeting human KAAG1. It is used for the treatment of advanced solid tumors including platinum resistant ovarian cancer and triple negative breast cancer. MW :145.28 KD.

Anti-KAAG1 (ADCT-901-MMAE) is an ADC composed of a humanized monoclonal antibody (3A4) targeting human KAAG1. It is used for the treatment of advanced solid tumors including platinum resistant ovarian cancer and triple negative breast cancer. MW :145.28 KD.

Anti-KAAG1 (ADCT-901-MMAE) is an ADC composed of a humanized monoclonal antibody (3A4) targeting human KAAG1. It is used for the treatment of advanced solid tumors including platinum resistant ovarian cancer and triple negative breast cancer. MW :145.28 KD.

Anti-KID3 is a monoclonal antibody (MAb) directed against KID3, a carbohydrate epitope found in the colon and several forms of cancer. MW: 147.04 KD.

Anti-KID3 is a monoclonal antibody (MAb) directed against KID3, a carbohydrate epitope found in the colon and several forms of cancer. MW: 147.04 KD.

Anti-KID3 is a monoclonal antibody (MAb) directed against KID3, a carbohydrate epitope found in the colon and several forms of cancer. MW: 147.04 KD.

Anti-KLK2 / Kallikrein 2 is a radioimmunoconjugate containing h11B6, a humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets human kallikrein-2 (hK2), conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA), and labeled with the alpha-emitting radioisotope actinium Ac 225, with potential antineoplastic activity. MW: 145.5 kD.

Anti-KLK2 / Kallikrein 2 is a radioimmunoconjugate containing h11B6, a humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets human kallikrein-2 (hK2), conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA), and labeled with the alpha-emitting radioisotope actinium Ac 225, with potential antineoplastic activity. MW: 145.5 kD.

Anti-KLK2 / Kallikrein 2 is a radioimmunoconjugate containing h11B6, a humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets human kallikrein-2 (hK2), conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA), and labeled with the alpha-emitting radioisotope actinium Ac 225, with potential antineoplastic activity. MW: 145.5 kD.

Anti-KLK5 / Kallikrein 5 is a monoclonal antibody kallikrein-related peptidase 5 (KLK5) with the potential to be used in research on immune-based therapies. MW: 144.76 KD.

Anti-KLK5 / Kallikrein 5 is a monoclonal antibody kallikrein-related peptidase 5 (KLK5) with the potential to be used in research on immune-based therapies. MW: 144.76 KD.

Anti-KLK5 / Kallikrein 5 is a monoclonal antibody kallikrein-related peptidase 5 (KLK5) with the potential to be used in research on immune-based therapies. MW: 144.76 KD.

Anti-Klotho Beta is an antibody targeting Beta Klotho (KLB). MW: 145.24 kD.

Anti-Klotho Beta is an antibody targeting Beta Klotho (KLB). MW: 145.24 kD.

Anti-Klotho Beta is an antibody targeting Beta Klotho (KLB). MW: 145.24 kD.

Anti-LAMP1 / CD107 is a monoclonal antibody against lysosome-associated membrane protein 1 (LAMP1) with potential antineoplastic activity. MW: 145.5 kD.

Anti-LAMP1 / CD107 is a monoclonal antibody against lysosome-associated membrane protein 1 (LAMP1) with potential antineoplastic activity. MW: 145.5 kD.

Anti-LAMP1 / CD107 is a monoclonal antibody against lysosome-associated membrane protein 1 (LAMP1) with potential antineoplastic activity. MW: 145.5 kD.

Anti-LCMV nucleoprotein-InVivo reacts with lymphocytic choriomeningitis virus (LCMV) nucleoprotein (NP), a 63 kDa structural protein.

Anti-LCMV nucleoprotein-InVivo reacts with lymphocytic choriomeningitis virus (LCMV) nucleoprotein (NP), a 63 kDa structural protein.

Anti-LCMV nucleoprotein-InVivo reacts with lymphocytic choriomeningitis virus (LCMV) nucleoprotein (NP), a 63 kDa structural protein.

Anti-LCMV nucleoprotein-InVivo reacts with lymphocytic choriomeningitis virus (LCMV) nucleoprotein (NP), a 63 kDa structural protein.

Anti-Lewis Y (MB 311) is a fully humanized monoclonal antibody recognizing the tumor-associated antigen Lewis Y. It represents an attractive target for cancer immunotherapy and can be used in treatment of breast cancer. MW 146.38 KD.

Anti-Lewis Y (MB 311) is a fully humanized monoclonal antibody recognizing the tumor-associated antigen Lewis Y. It represents an attractive target for cancer immunotherapy and can be used in treatment of breast cancer. MW 146.38 KD.

Anti-Lewis Y (MB 311) is a fully humanized monoclonal antibody recognizing the tumor-associated antigen Lewis Y. It represents an attractive target for cancer immunotherapy and can be used in treatment of breast cancer. MW 146.38 KD.

 Anti-Ly6E is an antibody against the tumor-associated antigen (TAA) lymphocyte antigen 6 complex locus E (Ly6E) with potential antineoplastic activity.MW: 145.5 kD.

 Anti-Ly6E is an antibody against the tumor-associated antigen (TAA) lymphocyte antigen 6 complex locus E (Ly6E) with potential antineoplastic activity.MW: 145.5 kD.

 Anti-Ly6E is an antibody against the tumor-associated antigen (TAA) lymphocyte antigen 6 complex locus E (Ly6E) with potential antineoplastic activity.MW: 145.5 kD.

Anti-LY75 / CD205 (CDX-1401) human monoclonal antibodies targeting specific for CD205 (DEC-205). It is used to enhance anticancer immunity by exploiting the capacity of dendritic cells (DCs). MW :150 KD.

Anti-LY75 / CD205 (CDX-1401) human monoclonal antibodies targeting specific for CD205 (DEC-205). It is used to enhance anticancer immunity by exploiting the capacity of dendritic cells (DCs). MW :150 KD.

Anti-LY75 / CD205 (CDX-1401) human monoclonal antibodies targeting specific for CD205 (DEC-205). It is used to enhance anticancer immunity by exploiting the capacity of dendritic cells (DCs). MW :150 KD.

Anti-MAGEA3 is an antibody that targets MAGE-A. It can be used in the treatment of metastatic cancer treatment. MW :145.56 KD.

Anti-MAGEA3 is an antibody that targets MAGE-A. It can be used in the treatment of metastatic cancer treatment. MW :145.56 KD.

Anti-MAGEA3 is an antibody that targets MAGE-A. It can be used in the treatment of metastatic cancer treatment. MW :145.56 KD.

Anti-Matriptase is a monoclonal matriptase-specific antibody. MW: 144.28 KD.

Anti-Matriptase is a monoclonal matriptase-specific antibody. MW: 144.28 KD.

Anti-Matriptase is a monoclonal matriptase-specific antibody. MW: 144.28 KD.

Anti-Melanotransferrin / CD228 is an antibody against the melanotransferrin with potential antineoplastic activity.MW: 145.5 kD.

Anti-Melanotransferrin / CD228 is an antibody against the melanotransferrin with potential antineoplastic activity.MW: 145.5 kD.

Anti-Melanotransferrin / CD228 is an antibody against the melanotransferrin with potential antineoplastic activity.MW: 145.5 kD.

Anti-MERS (2E6) is a human neutralizing antibody that targets competing for the binding of the virus Spike protein to the receptor (CD26). It is useful in inhibiting virus invasion into host cells. MW :150 KD.

Anti-MERS (2E6) is a human neutralizing antibody that targets competing for the binding of the virus Spike protein to the receptor (CD26). It is useful in inhibiting virus invasion into host cells. MW :150 KD.

Anti-MERS (2E6) is a human neutralizing antibody that targets competing for the binding of the virus Spike protein to the receptor (CD26). It is useful in inhibiting virus invasion into host cells. MW :150 KD.

Anti-MERS (3A1) is a human monoclonal IgG1 antibody targeting the binding of MERS-CoV spike protein to DPP4 receptor. It is useful in inhibiting virus invasion into host cells. MW :150 KD.

Anti-MERS (3A1) is a human monoclonal IgG1 antibody targeting the binding of MERS-CoV spike protein to DPP4 receptor. It is useful in inhibiting virus invasion into host cells. MW :150 KD.

Anti-MERS (3A1) is a human monoclonal IgG1 antibody targeting the binding of MERS-CoV spike protein to DPP4 receptor. It is useful in inhibiting virus invasion into host cells. MW :150 KD.